Carregant...
The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
A challenge for the clinician treating patients with multiple sclerosis (MS) is to determine the most effective treatment while weighing the benefits and risks. Results of the phase 2 and phase 3 studies on natalizumab were received with great interest, in part due to the “improved” risk reduction f...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Academy of Neurology
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2754334/ https://ncbi.nlm.nih.gov/pubmed/19770475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181b9c8f7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|